HRAS and neoplasm: Patient 1 received the combination of dabrafenib (RAFi) and trametinib (MEKi), and Patient 2 received trametinib (MEKi), treatment recommendations that were guided by tumor genetic profiling (BRAF p.V600E and HRAS p.G13R, respectively).